Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 160,000 shares at $73.64 ($12.1M) on 2026-01-08, disclosed to the SEC on 2026-01-12.
Open-market sale of $12.1M BBIO by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $73.64 | 11,515 | $848K | 7.0% |
| 2 | $73.64 | 11,515 | $848K | 7.0% |
| 3 | $73.65 | 11,565 | $852K | 7.0% |
| 4 | $73.65 | 11,565 | $852K | 7.0% |
| 5 | $74.38 | 8,085 | $601K | 5.0% |
| 6 | $74.38 | 8,135 |
| $605K |
| 5.0% |
| 7 | $74.38 | 8,135 | $605K | 5.0% |
| 8 | $74.38 | 8,085 | $601K | 5.0% |
| 9 | $75.16 | 400 | $30K | 0.2% |
| 10 | $75.16 | 400 | $30K | 0.2% |
| 11 | $75.20 | 300 | $23K | 0.2% |
| 12 | $75.20 | 300 | $23K | 0.2% |
| 13 | $75.61 | 1,401 | $106K | 0.9% |
| 14 | $75.61 | 1,401 | $106K | 0.9% |
| 15 | $75.75 | 2,151 | $163K | 1.3% |
| 16 | $75.75 | 2,151 | $163K | 1.3% |
| 17 | $76.53 | 6,067 | $464K | 3.8% |
| 18 | $76.53 | 6,067 | $464K | 3.8% |
| 19 | $76.72 | 6,955 | $534K | 4.4% |
| 20 | $76.72 | 6,955 | $534K | 4.4% |
| 21 | $77.46 | 10,677 | $827K | 6.8% |
| 22 | $77.46 | 10,677 | $827K | 6.8% |
| 23 | $77.61 | 10,519 | $816K | 6.8% |
| 24 | $77.61 | 10,519 | $816K | 6.8% |
| 25 | $78.10 | 1,855 | $145K | 1.2% |
| 26 | $78.10 | 1,855 | $145K | 1.2% |
| 27 | $78.19 | 375 | $29K | 0.2% |
| 28 | $78.19 | 375 | $29K | 0.2% |
| Total | $75.54 avg | 160,000 | $12.1M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |